"NIH Grant For Mount Sinai To Study Use Of Inhaled Corticosteroids For Treatment Of Sickle Cell Disease"
The Departments of Emergency Medicine and Hematology at the Icahn School of Medicine at Mount Sinai have been awarded a four million dollar grant from the National Institutes of Health toward further study of inhaled corticosteroids to treat sickle cell disease (SCD) in individuals who do not have asthma. The IMPROVE 2 study is a one-year-randomized placebo-controlled trial involving 80 SCD patients. Over the last decade, researchers at Mount Sinai have demonstrated that pulmonary inflammation is present in mice and humans with SCD. The research team will include experts in hematology, pulmonology, and immunology and will be led by Jeffrey Glassberg, MD, associate professor of emergency medicine, medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. “In sickle cell disease, the interaction between the lung and red blood cells represents a potentially high-value therapeutic target,” said Dr. Glassberg. Dr. Glassberg added that patients with SCD will often end up in the emergency department because they experience excruciating pain. He said alternative treatments will improve patient care, reduce ED visits, and lower healthcare expenditures.
- Jeffrey Glassberg, MD, Associate Professor, Emergency Medicine, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Director, Mount Sinai Comprehensive Program for Sickle Cell Disease
Additional coverage:
Crain’s Health Pulse (Subscription required)